Will Hodgkin Lymphoma Patients Benefit From Checkpoint Inhibitors?

Published on

Topics include: Treatments

Do checkpoint inhibitors have a role in Hodgkin lymphoma care as a frontline treatment? Leading Hodgkin lymphoma experts Dr. Andrew Evens, from Rutgers Cancer Institute of New Jersey, and Dr. Joshua Brody, from Icahn School of Medicine at Mount Sinai, discuss the latest research developments on treatment strategies with new immunotherapy approaches and current FDA approvals. The panel also announces an upcoming North American clinical trial for Hodgkin lymphoma with checkpoint inhibitors. Watch now to find out more.

This program is sponsored through a grant from Seattle Genetics. This organization has no editorial control. It is produced solely by Patient Power.

View more programs featuring , and

Transcript

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.

Andrew Schorr:  

So, some people in the last year or two have seen these TV ads for lung cancer, which are really folks referring to this sort of checkpoint inhibitor approach. So, what you’re saying is what they’ve been having success with for some people for lung cancer and melanoma could pay off for Hodgkin’s.

Dr. Brody:            

Already paying off today, and then, the big question is—again, they are now FDA-approved for Hodgkin’s lymphoma and the third line of therapy after chemotherapy and maybe the transplant hasn’t worked. So, the question is how can we bring these from third-line treatment maybe to second-line and possibly even to front-line treatment?

Dr. Evens:

And, it is going front-line. I guess I could announce it. Our new North American clinical trial in the United States is not open yet. It’s called S-1826. It’s going to be led by SWOG.

Esther Schorr:     

“SWOG”?

Andrew Schorr:  

Southwestern Oncology Group.

Esther Schorr:     

Ah, thank you.

Andrew Schorr:  

It’s a medical cooperative.

Dr. Evens:             

Too many acronyms, sorry.

Dr. Brody:            

You thought it was a person named “SWOG”?

Esther Schorr:     

Maybe. Who is this guy?

Dr. Evens:             

That does sound like a pretty good nickname. I’m gonna start calling you “SWOG.” Call me “ECOG.” So, really, it’s a big effort. It’s led by that cooperative group, and it’s going to look at a checkpoint front-line, nivolumab, combined with AVD. There hasn’t been a huge experience, but it’s really gone fast, but I think the momentum is there.

The standard arm—it was a lot of debate about that, actually—is going to be the Echelon 1 brentuximab vedotin (Adcetris) AVD arm, but it’s going to be not only a large study, it’s going to be all of North America—so, U.S., Canada—and the Children’s Oncology Group, believe it or not, is going to participate on that, so, all the way down to age 12. I can’t say it’s an all-age study, but one of the first times we’ve actually collaborated together, which we’re doing more of, because whether you’re Hodgkin’s in a 16-year-old or 25-year-old, one might be treated by a pediatrician and another by an adult oncologist, but we face the same issues.

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.

Related Programs

What Is the Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma Patients?

What happens if a Hodgkin lymphoma patient relapses after frontline therapy? Listen as expert Dr. Joshua Brody shares advances in treatment for relapsed/refractory disease announced at ASH 2018.

Published:

Immunotherapy for Hodgkin Lymphoma

Are there Hodgkin lymphoma treatments on the horizon that can use a patient’s immune system against cancer? Watch as experts share research updates on treatments in development.

Published:

Treatment Developments and Ongoing Hodgkin Lymphoma Research

Expert Dr. John Burke discusses what’s new in the world of Hodgkin lymphoma. Watch now to learn about new studies on the use of radiation, how to treat early stage patients, and more.

Published:

Advertisement
Join Our Community Register for Events Read Our Latest Blog
Advertisement

Page last updated on September 9, 2019